137 related articles for article (PubMed ID: 38677725)
1. Effect of MYC and PARP Inhibitors in Ovarian Cancer Using an
Morea A; Saravi S; Sisu C; Hall M; Tosi S; Karteris E; Storlazzi CT
Anticancer Res; 2024 May; 44(5):1817-1827. PubMed ID: 38677725
[TBL] [Abstract][Full Text] [Related]
2. High amplification of PVT1 and MYC predict favorable prognosis in early ovarian carcinoma.
Yamamoto A; Kurata M; Yamamoto K; Nogawa D; Inoue M; Ishibashi S; Ikeda M; Miyasaka N; Kitagawa M
Pathol Res Pract; 2020 Nov; 216(11):153175. PubMed ID: 32841774
[TBL] [Abstract][Full Text] [Related]
3. Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer.
Guan Y; Kuo WL; Stilwell JL; Takano H; Lapuk AV; Fridlyand J; Mao JH; Yu M; Miller MA; Santos JL; Kalloger SE; Carlson JW; Ginzinger DG; Celniker SE; Mills GB; Huntsman DG; Gray JW
Clin Cancer Res; 2007 Oct; 13(19):5745-55. PubMed ID: 17908964
[TBL] [Abstract][Full Text] [Related]
4. PVT1 dependence in cancer with MYC copy-number increase.
Tseng YY; Moriarity BS; Gong W; Akiyama R; Tiwari A; Kawakami H; Ronning P; Reuland B; Guenther K; Beadnell TC; Essig J; Otto GM; O'Sullivan MG; Largaespada DA; Schwertfeger KL; Marahrens Y; Kawakami Y; Bagchi A
Nature; 2014 Aug; 512(7512):82-6. PubMed ID: 25043044
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
Cho HY; Kim YB; Park WH; No JH
Cancer Res Treat; 2021 Jul; 53(3):819-828. PubMed ID: 33332934
[TBL] [Abstract][Full Text] [Related]
6. BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.
Lui GYL; Shaw R; Schaub FX; Stork IN; Gurley KE; Bridgwater C; Diaz RL; Rosati R; Swan HA; Ince TA; Harding TC; Gadi VK; Goff BA; Kemp CJ; Swisher EM; Grandori C
EBioMedicine; 2020 Oct; 60():102988. PubMed ID: 32927276
[TBL] [Abstract][Full Text] [Related]
7. Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma.
Riquelme E; Suraokar MB; Rodriguez J; Mino B; Lin HY; Rice DC; Tsao A; Wistuba II
J Thorac Oncol; 2014 Jul; 9(7):998-1007. PubMed ID: 24926545
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.
Shen YA; Hong J; Asaka R; Asaka S; Hsu FC; Suryo Rahmanto Y; Jung JG; Chen YW; Yen TT; Tomaszewski A; Zhang C; Attarwala N; DeMarzo AM; Davidson B; Chuang CM; Chen X; Gaillard S; Le A; Shih IM; Wang TL
Cancer Res; 2020 Oct; 80(20):4514-4526. PubMed ID: 32859605
[TBL] [Abstract][Full Text] [Related]
9. A pan-cancer analysis of MYC-PVT1 reveals CNV-unmediated deregulation and poor prognosis in renal carcinoma.
Posa I; Carvalho S; Tavares J; Grosso AR
Oncotarget; 2016 Jul; 7(30):47033-47041. PubMed ID: 27366943
[TBL] [Abstract][Full Text] [Related]
10. MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer.
Yi J; Liu C; Tao Z; Wang M; Jia Y; Sang X; Shen L; Xue Y; Jiang K; Luo F; Liu P; Cheng H
EBioMedicine; 2019 May; 43():225-237. PubMed ID: 30898650
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.
Ihnen M; zu Eulenburg C; Kolarova T; Qi JW; Manivong K; Chalukya M; Dering J; Anderson L; Ginther C; Meuter A; Winterhoff B; Jones S; Velculescu VE; Venkatesan N; Rong HM; Dandekar S; Udar N; Jänicke F; Los G; Slamon DJ; Konecny GE
Mol Cancer Ther; 2013 Jun; 12(6):1002-15. PubMed ID: 23729402
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA PVT1-mediated miR-543/SERPINI1 axis plays a key role in the regulatory mechanism of ovarian cancer.
Qu C; Dai C; Guo Y; Qin R; Liu J
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32441301
[TBL] [Abstract][Full Text] [Related]
13. Long non-coding RNA PVT1 promotes cell proliferation and invasion through regulating miR-133a in ovarian cancer.
Yang Q; Yu Y; Sun Z; Pan Y
Biomed Pharmacother; 2018 Oct; 106():61-67. PubMed ID: 29957467
[TBL] [Abstract][Full Text] [Related]
14. Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease.
Dal Molin GZ; Westin SN; Coleman RL
Future Oncol; 2018 Dec; 14(30):3101-3110. PubMed ID: 30105925
[TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis.
Jin K; Wang S; Zhang Y; Xia M; Mo Y; Li X; Li G; Zeng Z; Xiong W; He Y
Cell Mol Life Sci; 2019 Nov; 76(21):4275-4289. PubMed ID: 31309249
[TBL] [Abstract][Full Text] [Related]
16. Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells.
Perez JM; Twigg CAI; Guan W; Thomas SN
J Am Soc Mass Spectrom; 2022 Feb; 33(2):242-250. PubMed ID: 34958553
[TBL] [Abstract][Full Text] [Related]
17. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition.
Gabbasov R; Benrubi ID; O'Brien SW; Krais JJ; Johnson N; Litwin S; Connolly DC
Cancer Biol Ther; 2019; 20(7):1035-1045. PubMed ID: 30929564
[TBL] [Abstract][Full Text] [Related]
18. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
19. Rucaparib in the landscape of PARP inhibition in ovarian cancer.
Colomba E; Pautier P; Pommeret F; Leary A
Expert Rev Anticancer Ther; 2019 Jun; 19(6):437-446. PubMed ID: 30977683
[No Abstract] [Full Text] [Related]
20. How safe is rucaparib in ovarian cancer?
Cosgrove CM; O'Malley DM
Expert Opin Drug Saf; 2018 Dec; 17(12):1249-1255. PubMed ID: 30449210
[No Abstract] [Full Text] [Related]
[Next] [New Search]
